Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibition
- Autores
- Richard, Silvina Mariel; Martínez Marignac, Verónica Lucrecia
- Año de publicación
- 2015
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Aim of study: In the present study, we evaluated the effect of ribavirin and metformin on the sensitivity of oxaliplatin and 5-fluorouracil (5-FU) on colon cancer. Materials and Methods: Cell viability of two commercially available colon cancer cell lines (HT29 and HCT116) were analyzed by sulforhodamine B (SRB) assay. Results: A clinically achievable and nontoxic concentration of ribavirin and metformin showed a significant synergistic effect on oxaliplatin in HT29 and HCT116 cell lines. Ribavirin showed a synergistic effect on oxaliplatin in HT29 (R = 2.93, P < 0.001) and HCT116 (R = 1.71, P < 0.001), while only in HT29 metformin synergized with oxaliplatin by 2.66 (± 0.28, P < 0.01). In addition, both cell lines showed significant differences in response to Compound 968, inhibitor of mitochondrial glutaminase activity. Conclusion: The data suggested that these cell lines not only turn to metabolic different sustainability process after oxaliplatin treatment but that they also have different basal metabolic requirements of glutamine in vitro which can be exploits in the future for colorectal cancer (CRC) treatment and further studies are required.
Instituto Multidisciplinario de Biología Celular - Materia
-
Ciencias Exactas
Ciencias Médicas
5-FU
Colorectal cancer
Metformin
Oxaliplatin
Ribavirin - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- http://creativecommons.org/licenses/by-nc-sa/4.0/
- Repositorio
.jpg)
- Institución
- Universidad Nacional de La Plata
- OAI Identificador
- oai:sedici.unlp.edu.ar:10915/99691
Ver los metadatos del registro completo
| id |
SEDICI_ba68415c202eace93d6a217d3d02c094 |
|---|---|
| oai_identifier_str |
oai:sedici.unlp.edu.ar:10915/99691 |
| network_acronym_str |
SEDICI |
| repository_id_str |
1329 |
| network_name_str |
SEDICI (UNLP) |
| spelling |
Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibitionRichard, Silvina MarielMartínez Marignac, Verónica LucreciaCiencias ExactasCiencias Médicas5-FUColorectal cancerMetforminOxaliplatinRibavirin<b>Aim of study:</b> In the present study, we evaluated the effect of ribavirin and metformin on the sensitivity of oxaliplatin and 5-fluorouracil (5-FU) on colon cancer. <b>Materials and Methods:</b> Cell viability of two commercially available colon cancer cell lines (HT29 and HCT116) were analyzed by sulforhodamine B (SRB) assay. <b>Results:</b> A clinically achievable and nontoxic concentration of ribavirin and metformin showed a significant synergistic effect on oxaliplatin in HT29 and HCT116 cell lines. Ribavirin showed a synergistic effect on oxaliplatin in HT29 (R = 2.93, P < 0.001) and HCT116 (R = 1.71, P < 0.001), while only in HT29 metformin synergized with oxaliplatin by 2.66 (± 0.28, P < 0.01). In addition, both cell lines showed significant differences in response to Compound 968, inhibitor of mitochondrial glutaminase activity. <b>Conclusion:</b> The data suggested that these cell lines not only turn to metabolic different sustainability process after oxaliplatin treatment but that they also have different basal metabolic requirements of glutamine <i>in vitro</i> which can be exploits in the future for colorectal cancer (CRC) treatment and further studies are required.Instituto Multidisciplinario de Biología Celular2015-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdf336-340http://sedici.unlp.edu.ar/handle/10915/99691enginfo:eu-repo/semantics/altIdentifier/url/https://ri.conicet.gov.ar/11336/53494info:eu-repo/semantics/altIdentifier/url/http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2015;volume=11;issue=2;spage=336;epage=340;aulast=Richardinfo:eu-repo/semantics/altIdentifier/issn/1998-4138info:eu-repo/semantics/altIdentifier/doi/10.4103/0973-1482.157317info:eu-repo/semantics/altIdentifier/hdl/11336/53494info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-10-15T11:12:04Zoai:sedici.unlp.edu.ar:10915/99691Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-10-15 11:12:04.713SEDICI (UNLP) - Universidad Nacional de La Platafalse |
| dc.title.none.fl_str_mv |
Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibition |
| title |
Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibition |
| spellingShingle |
Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibition Richard, Silvina Mariel Ciencias Exactas Ciencias Médicas 5-FU Colorectal cancer Metformin Oxaliplatin Ribavirin |
| title_short |
Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibition |
| title_full |
Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibition |
| title_fullStr |
Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibition |
| title_full_unstemmed |
Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibition |
| title_sort |
Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibition |
| dc.creator.none.fl_str_mv |
Richard, Silvina Mariel Martínez Marignac, Verónica Lucrecia |
| author |
Richard, Silvina Mariel |
| author_facet |
Richard, Silvina Mariel Martínez Marignac, Verónica Lucrecia |
| author_role |
author |
| author2 |
Martínez Marignac, Verónica Lucrecia |
| author2_role |
author |
| dc.subject.none.fl_str_mv |
Ciencias Exactas Ciencias Médicas 5-FU Colorectal cancer Metformin Oxaliplatin Ribavirin |
| topic |
Ciencias Exactas Ciencias Médicas 5-FU Colorectal cancer Metformin Oxaliplatin Ribavirin |
| dc.description.none.fl_txt_mv |
<b>Aim of study:</b> In the present study, we evaluated the effect of ribavirin and metformin on the sensitivity of oxaliplatin and 5-fluorouracil (5-FU) on colon cancer. <b>Materials and Methods:</b> Cell viability of two commercially available colon cancer cell lines (HT29 and HCT116) were analyzed by sulforhodamine B (SRB) assay. <b>Results:</b> A clinically achievable and nontoxic concentration of ribavirin and metformin showed a significant synergistic effect on oxaliplatin in HT29 and HCT116 cell lines. Ribavirin showed a synergistic effect on oxaliplatin in HT29 (R = 2.93, P < 0.001) and HCT116 (R = 1.71, P < 0.001), while only in HT29 metformin synergized with oxaliplatin by 2.66 (± 0.28, P < 0.01). In addition, both cell lines showed significant differences in response to Compound 968, inhibitor of mitochondrial glutaminase activity. <b>Conclusion:</b> The data suggested that these cell lines not only turn to metabolic different sustainability process after oxaliplatin treatment but that they also have different basal metabolic requirements of glutamine <i>in vitro</i> which can be exploits in the future for colorectal cancer (CRC) treatment and further studies are required. Instituto Multidisciplinario de Biología Celular |
| description |
<b>Aim of study:</b> In the present study, we evaluated the effect of ribavirin and metformin on the sensitivity of oxaliplatin and 5-fluorouracil (5-FU) on colon cancer. <b>Materials and Methods:</b> Cell viability of two commercially available colon cancer cell lines (HT29 and HCT116) were analyzed by sulforhodamine B (SRB) assay. <b>Results:</b> A clinically achievable and nontoxic concentration of ribavirin and metformin showed a significant synergistic effect on oxaliplatin in HT29 and HCT116 cell lines. Ribavirin showed a synergistic effect on oxaliplatin in HT29 (R = 2.93, P < 0.001) and HCT116 (R = 1.71, P < 0.001), while only in HT29 metformin synergized with oxaliplatin by 2.66 (± 0.28, P < 0.01). In addition, both cell lines showed significant differences in response to Compound 968, inhibitor of mitochondrial glutaminase activity. <b>Conclusion:</b> The data suggested that these cell lines not only turn to metabolic different sustainability process after oxaliplatin treatment but that they also have different basal metabolic requirements of glutamine <i>in vitro</i> which can be exploits in the future for colorectal cancer (CRC) treatment and further studies are required. |
| publishDate |
2015 |
| dc.date.none.fl_str_mv |
2015-04 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Articulo http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://sedici.unlp.edu.ar/handle/10915/99691 |
| url |
http://sedici.unlp.edu.ar/handle/10915/99691 |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://ri.conicet.gov.ar/11336/53494 info:eu-repo/semantics/altIdentifier/url/http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2015;volume=11;issue=2;spage=336;epage=340;aulast=Richard info:eu-repo/semantics/altIdentifier/issn/1998-4138 info:eu-repo/semantics/altIdentifier/doi/10.4103/0973-1482.157317 info:eu-repo/semantics/altIdentifier/hdl/11336/53494 |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) |
| dc.format.none.fl_str_mv |
application/pdf 336-340 |
| dc.source.none.fl_str_mv |
reponame:SEDICI (UNLP) instname:Universidad Nacional de La Plata instacron:UNLP |
| reponame_str |
SEDICI (UNLP) |
| collection |
SEDICI (UNLP) |
| instname_str |
Universidad Nacional de La Plata |
| instacron_str |
UNLP |
| institution |
UNLP |
| repository.name.fl_str_mv |
SEDICI (UNLP) - Universidad Nacional de La Plata |
| repository.mail.fl_str_mv |
alira@sedici.unlp.edu.ar |
| _version_ |
1846064177953636352 |
| score |
13.22299 |